Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat

Regulatory Peptides

Volumn 176, Issue 1-3, 2012, Pages 36-44

  Whaley Connell, Adam ^a,b,d   Habibi, Javad ^a,c,d   Nistala, Ravi ^a,b,d,e   Hayden, Melvin R ^a,c,d   Pulakat, Lakshmi ^a,c,d   Sinak, Catherine ^a,d   Locher, Bonnie ^a,d   Ferrario, Carlos M ^f   Sowers, James R ^a,c,d  

^a University of Missouri   (United States)

^b Division of Nephrology and Hypertension   (United States)

^c Division of Endocrinology and Metabolism   (United States)

^d Diabetes and Cardiovascular Center   (United States)

^e Dialysis Clinics Inc   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; AT1R blockade; Combination; Oxidative stress; Renin inhibition

Indexed keywords

3 NITROTYROSINE; ALDOSTERONE; ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLLAGEN TYPE 3; FIBRONECTIN; MEGALIN; N ACETYL BETA GLUCOSAMINIDASE; PODOCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; RENIN; VALSARTAN;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ENDOSOME; GLOMERULUS; HYPERTENSION; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; LYSOSOME; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; RAT STRAIN; RECEPTOR BLOCKING; REN2 RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; SYSTOLIC HYPERTENSION; TRANSGENIC RAT; TREATMENT DURATION; URINE LEVEL;

ACUTE KIDNEY INJURY; ALDOSTERONE; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; FUMARATES; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; TETRAZOLES; VALINE;

ANIMALIA; RATTUS;

EID: 84860597601     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.03.002     Document Type: Article

References (48)

1. Nistala R., Whaley-Connell A., Sowers J.R. Redox control of renal function and hypertension. Antioxid Redox Signal 2008, 10(12):2047-2089.
2. Jaimes E.A., Hua P., Tian R.X., Raij L. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol 2010, 298(1):F125-F132.
3. Fujii H., Kono K., Nakai K., Goto S., Komaba H., Hamada Y., Shinohara M., Kitazawa R., Kitazawa S., Fukagawa M. Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol 2010, 31(4):342-352.
4. Rossing P., Hommel E., Smidt U.M., Parving H.H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994, 37(5):511-516.
5. Kalaitzidis R., Bakris G.L. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens 2009, 27(5):S15-S21.
6. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23):2433-2446.
7. Epstein M., Williams G.H., Weinberger M., Lewin A., Krause S., Mukherjee R., Patni R., Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1(5):940-951.
8. Foley R.N., Collins A.J. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007, 18(10):2644-2648.
9. Holtkamp F.A., de Zeeuw D., de Graeff P.A., Laverman G.D., Berl T., Remuzzi G., Packham D., Lewis J.B., Parving H.H., Lambers Heerspink H.J. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011, 32(12):1493-1499.
10. Sowers J.R., Whaley-Connell A., Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
11. Bomback A.S., Klemmer P.J. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-492.
12. Hollenberg N.K., Fisher N.D., Price D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387-392.
13. Wiggins K.J., Kelly D.J. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney Int 2009, 76:23-31.
14. 1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010, 298(3):F655-F661.
15. Yamaguchi T., Tokita Y., Franco-Saenz R., Mulrow P.J., Peters J., Ganten D. Zonal distribution and regulation of adrenal renin in a transgenic model of hypertension in the rat. Endocrinology 1992, 131(4):1955-1962.
16. Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., Mueller D.N., Feldt S., Cumin F., Maniara W., Persohn E., Schuetz H., Jan Danser A.H., Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52(1):130-136.
17. Nguyen G., Danser A.H.J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008, 93:557-563.
18. Nguyen G., Delarue F., Berrou J., Rondeau E., Sraer J.D. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897-1903.
19. Kelly D.J., Zhang Y., Moe G., Naik G., Gilbert R.E. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007, 50:2398-2404.
20. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
21. Blundell T., Sibanda B.L., Pearl L. Three-dimensional structure, specificity and catalytic mechanism of renin. Nature 1983, 304(5923):273-275.
22. Lu H., Rateri D.L., Feldman D.L., Jr RJ, Fukamizu A., Ishida J., Oesterling E.G., Cassis L.A., Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008, 118(3):984-993.
23. Bohlender J., Menard J., Edling O., Ganten D., Luft F.C. Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats. Am J Physiol 1998, 274(5 Pt 2):H1450-H1456.
24. Whaley-Connell A.T., Chowdhury N.A., Hayden M.R., Stump C.S., Habibi J., Wiedmeyer C.E., Gallagher P.E., Tallant E.A., Cooper S.A., Link C.D., Ferrario C., Sowers J.R. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006, 291(6):F1308-F1314.
25. Whaley-Connell A., Habibi J., Nistala R., Cooper S.A., Karuparthi P.R., Hayden M.R., Rehmer N., DeMarco V.G., Andresen B.T., Wei Y., Ferrario C., Sowers J.R. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008, 51(2):474-480.
26. Whaley-Connell A., Habibi J., Wei Y., Gutweiler A., Jellison J., Wiedmeyer C.E., Ferrario C.M., Sowers J.R. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009, 296(5):F1013-F1022.
27. Lee M.A., Bohm M., Paul M., Bader M., Ganten U., Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol Endocrinol Metab 1996, 270:E919-E929.
28. Shibata S., Nagase M., Yoshida S., Kawachi H., Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364.
29. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt sensitive rats and is reversed by aldosterone blocker. Hypertension 2006, 471:1084-1093.
30. Habibi J., DeMarco V.G., Ma L., Pulakat L., Rainey W.E., Whaley-Connell A.T., Sowers J.R. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 2011, 300(4):H1484-H1491.
31. Johnstone D.B., Holtzman L.B. Clinical impact of research on the podocyte slit diaphragm. Nat Clin Pract Nephrol 2006, 2:271-282.
32. Russo L.M., Sandoval R.M., Campos S.B., Molitoris B.A., Comper W.D., Brown D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009, 20(3):489-494.
33. Langheinrich M., Lee M.A., Böhm M., Pinto Y.M., Ganten D., Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996, 9(5):506-512.
34. Peters J., Ganten D. Adrenal renin expression and its role in Ren2 transgenic rats TGR(mREN2)27. Horm Metab Res 1998, 30(6-7):350-354.
35. Böhm M., Lee M., Kreutz R., Kim S., Schinke M., Djavidani B., Wagner J., Kaling M., Wienen W., Bader M., et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995, 13(8):891-899.
36. Azizi M., Ménard J., Bissery A., Guyene T.T., Bura-Rivière A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007, 2(5):947-955.
37. Rocco S., Rebuffat P., Cimolato M., Opocher G., Peters J., Mazzocchi G., Ganten D., Mantero F., Nussdorfer G.G. Zona glomerulosa of the adrenal gland in a transgenic strain of rat: a morphologic and functional study. Cell Tissue Res 1994, 278(1):21-28.
38. Peters J., Münter K., Bader M., Hackenthal E., Mullins J.J., Ganten D. Increased adrenal renin in transgenic hypertensive rats, TGR(mREN2)27, and its regulation by cAMP, angiotensin II, and calcium. J Clin Invest 1993, 91(3):742-747.
39. Whaley-Connell A., Govindarajan G., Habibi J., Hayden M.R., Cooper S.A., Wei Y., Ma L., Qazi M., Link D., Karuparthi P.R., Stump C., Ferrario C., Sowers J.R. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab 2007, 293(1):E355-E363.
40. 2 Contributes to Angiotensin II-induced Aldosterone Synthesis in Human and Rat Adrenal Cortical Cells. Antioxid Redox Signal Mar 2 2012, [Electronic publication ahead of print].
41. Yamamoto E., Kataoka K., Dong Y.F., Nakamura T., Fukuda M., Tokutomi Y., Matsuba S., Nako H., Nakagata N., Kaneko T., Ogawa H., Kim-Mitsuyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54(3):633-638.
42. Dong Y.F., Liu L., Lai Z.F., Yamamoto E., Kataoka K., Nakamura T., Fukuda M., Tokutomi Y., Nako H., Ogawa H., Kim-Mitsuyama S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010, 28(7):1554-1565.
43. Wu W.P., Chang C.H., Chiu Y.T., Ku C.L., Wen M.C., Shu K.H., Wu M.J. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol 2010, 299(5):F929-F941.
44. Trachtman H., Weiser A.C., Valderrama E., Morgado M., Palmer L.S. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004, 172(4 Pt 2):1590-1594.
45. Tojo A., Onozato M.L., Kurihara H., Sakai T., Goto A., Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003, 26(5):413-419.
46. Hosojima M., Sato H., Yamamoto K., Kaseda R., Soma T., Kobayashi A., Suzuki A., Kabasawa H., Takeyama A., Ikuyama K., Iino N., Nishiyama A., Thekkumkara T.J., Takeda T., Suzuki Y., Gejyo F., Saito A. Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor-and insulin mediated signaling cross talk. Endocrinology 2009, 150(2):871-878.
47. Drumm K., Kress T.R., Gassner B., Krug A.W., Gekle M. Aldosterone stimulates activity and surface expression of NHE3 in human primary proximal tubule epithelial cells (RPTEC). Cell Physiol Biochem 2006, 17(1-2):21-28.
48. Verroust P.J., Birn H., Nielsen R., Kozyraki R., Christensen E.I. The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002, 62(3):745-756.